Abstract | BACKGROUND: STUDY: CD patients intolerant of azathioprine/6-MP were offered leflunomide treatment. The Harvey-Bradshaw (H-B) disease activity index, global assessment, serologic parameters and ability to taper corticosteroids of those who accepted were retrospectively assessed. RESULTS:
Leflunomide was well tolerated and resulted in a significant reduction in the H-B score, global assessment and serologic parameters in 8/12 patients. Average follow-up was 38 weeks and a majority of steroid-dependent patients were able to successfully taper following leflunomide initiation. CONCLUSIONS: Our case series demonstrates that the pyrimidine analog leflunomide may be effective for treating moderate to severe CD patients intolerant to standard immunomodulator therapy and warrants further investigation in a randomized controlled trial.
|
Authors | Devang N Prajapati, Joshua F Knox, Jeanne Emmons, Kia Saeian, Mary E Csuka, David G Binion |
Journal | Journal of clinical gastroenterology
(J Clin Gastroenterol)
Vol. 37
Issue 2
Pg. 125-8
(Aug 2003)
ISSN: 0192-0790 [Print] United States |
PMID | 12869881
(Publication Type: Journal Article)
|
Chemical References |
- Adjuvants, Immunologic
- Immunosuppressive Agents
- Isoxazoles
- Leflunomide
|
Topics |
- Adjuvants, Immunologic
(therapeutic use)
- Adult
- Aged
- Crohn Disease
(drug therapy)
- Female
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Isoxazoles
(therapeutic use)
- Leflunomide
- Male
- Middle Aged
- Retrospective Studies
- Treatment Failure
|